Daraxonrasib extends survival in metastatic pancreatic cancer
1. Daraxonrasib is the first-in-class RAS inhibitor approved for metastatic pancreatic adenocarcinoma, addressing a molecular pathway that drives most pancreatic cancers but has historically been difficult to target pharmacologically.
2. In the randomized RASolute 302 trial, daraxonrasib extended median overall survival from 6.7 to 13.2 months and median progression-free survival from 3.6 to 7.2 months compared with standard chemotherapy.
Pancreatic adenocarcinoma has remained one of the most difficult solid tumors to treat, in part because alterations involving rat sarcoma (RAS) proteins are extraordinarily common while the pathway itself has historically resisted direct pharmacologic inhibition. On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved Rasonque (daraxonrasib), an oral RAS inhibitor for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval was supported by RASolute 302, a randomized, open-label, multicenter trial involving 500 patients with previously treated metastatic disease. Median overall survival was 13.2 months with daraxonrasib compared with 6.7 months with standard chemotherapy, corresponding to a hazard ratio of 0.40 and representing a substantial reduction in the risk of death during the study period. Median progression-free survival was similarly prolonged at 7.2 months versus 3.6 months, while the objective response rate was 30% with daraxonrasib compared with 11% with chemotherapy. The magnitude of benefit is particularly notable in metastatic pancreatic adenocarcinoma, where survival after disease progression remains poor and advances have more often produced incremental rather than dramatic improvements. These data establish direct RAS inhibition as a clinically consequential treatment strategy in pancreatic cancer rather than simply demonstrating that a historically difficult molecular target can be pharmacologically engaged.
Daraxonrasib is administered once daily, providing an oral alternative to additional intravenous chemotherapy for eligible patients with previously treated metastatic disease. Common adverse effects include rash, diarrhea, stomatitis, nausea, fatigue, vomiting, abdominal pain, edema, decreased appetite, and hemorrhage, requiring clinicians to balance the survival benefit against treatment-related toxicity and individual functional status. The prescribing information also includes warnings and precautions for serious complications including gastrointestinal perforation and interstitial lung disease or pneumonitis. The indication is defined by clinical setting rather than suggesting that every patient with a RAS-driven pancreatic tumor should receive the drug earlier in treatment, and its role in first-line combinations or earlier-stage disease remains to be established. Molecular heterogeneity within RAS-driven tumors also makes future work important for identifying which patients derive the greatest magnitude and duration of benefit and how resistance emerges during therapy. For oncologists, the immediate result is nevertheless unusually tangible because the randomized evidence demonstrates improvements in overall survival, progression-free survival, and objective response rather than relying on a surrogate endpoint alone. Daraxonrasib therefore represents an important shift in pancreatic cancer therapy, showing that direct targeting of a pathway once considered effectively undruggable can translate into a substantial survival advantage for patients with metastatic disease.
Image: PD
©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.
